In this issue:
- ctDNA-guided adjuvant atezolizumab in muscle invasive bladder cancer
- Immunotherapy prescribing and immune-related adverse events in head and neck cancer
- Deep-learning serial CT for predicting survival in ICI-treated NSCLC
- Time-of-day immunochemotherapy in NSCLC
- Adding FMT to immunotherapy in NSCLC or melanoma
- Anti-Claudin18.2×CD3 bispecific antibody for solid tumours, including gastric/ gastro-oesophageal
- Real-world neoadjuvant therapy ± pembrolizumab for triple-negative breast cancer
- First-line ipilimumab nivolumab in advanced Merkel cell carcinoma
- Real-world immunotherapy discontinuation at 2 years in advanced NSCLC
- Pembrolizumab for recurrent/ metastatic medullary thyroid cancer
Please login below to download this issue (PDF)